Pharmacopeia, Inc. (ACCL) (Prev: PCOP) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacopeia, Inc. (ACCL) (Prev: PCOP)

ACCL 4.000

-1.2%

Nov 5 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Lang who wrote (80)	5/17/1998 3:26:00 PM
From: kinkblot	Read Replies (1) of 179

Thread, The current (May/June) issue of Technology Review has an article "Winning Combination" on combinatorial materials research [not available online]. I believe Pharmacopeia mentioned this in their conference call after the MSI acquisition as an area where they expect some synergy, since MSI is a leading supplier of simulation software for materials science. Over 80% of the top 50 chemical companies use their software. They have particular strength in the areas of catalysts and polymers, for which they've established consortia: msi.com According to the article, the approach is just beginning to take off. Initial target compounds of research include catalysts, phosphors, polymers, capacitors and high Tc superconductors. The tough part is devising screening techniques to test the arrays of compounds for desired physical properties, which is more difficult than screening for biological activity. The article mentions Symyx Technologies as an early leader - their biggest achievement so far has been finding a new type of bright blue phosphor using the technique. Will

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next